• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by LB Pharmaceuticals Inc

    1/21/26 8:13:39 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LBRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    LB Pharmaceuticals Inc

    (Name of Issuer)


    Common Stock, $0.0001 par value

    (Title of Class of Securities)


    50180M108

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    50180M108


    1Names of Reporting Persons

    JPMORGAN CHASE & CO.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,471,295.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,611,482.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,611,482.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    LB Pharmaceuticals Inc
    (b)Address of issuer's principal executive offices:

    One Pennsylvania Plaza Suite 1025 New York NY 10119
    Item 2. 
    (a)Name of person filing:

    JPMORGAN CHASE & CO.
    (b)Address or principal business office or, if none, residence:

    270 Park Avenue,,New York, NY 10017
    (c)Citizenship:

    DE
    (d)Title of class of securities:

    Common Stock, $0.0001 par value
    (e)CUSIP No.:

    50180M108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1611482
    (b)Percent of class:

    6.3  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1471295

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    1611482

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    JPMorgan Chase Bank, National Association; J.P. Morgan Investment Management Inc.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    JPMORGAN CHASE & CO.
     
    Signature:Rachel Tsvaygoft
    Name/Title:Vice President
    Date:01/21/2026
    Get the next $LBRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LBRX

    DatePrice TargetRatingAnalyst
    1/9/2026Buy
    Roth Capital
    10/6/2025$27.00Buy
    Stifel
    10/6/2025$78.00Overweight
    Piper Sandler
    10/6/2025$34.00Outperform
    Leerink Partners
    More analyst ratings

    $LBRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

    NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the presentation of new data further evaluating the effects of LB-102 on cognitive performance in the Phase 2 NOVA-1 clinical trial in patients with acute schizophrenia. LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic

    3/27/26 12:00:00 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    Reported positive results from potentially registrational Phase 2 trial ofLB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple indications with initiation ofa pivotal Phase 3 NOVA-2 trial in schizophrenia, and Phase 2 ILLUMINATE-1 trialin bipolar depression Announced pipeline expansion with plans to initiate a Phase 2 trial of LB-102 for theadjunctive treatment of major depressive disorder (MDD) in early 2027 Cash, cash equivalents, and investments of $295.2 million as of December 31, 2025, and proceeds from recent $100 million private placement, expected to provide cash runway into Q2 2029 NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc

    3/26/26 4:05:00 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

    LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week 6; secondary endpoints to include evaluations of negative symptoms and cognitive performance as well as safety and tolerability Topline data expected in 2H 2027 NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the ini

    3/25/26 8:00:00 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Deep Track Biotechnology Master Fund, Ltd. converted options into 686,138 shares and bought $39,999,990 worth of shares (2,666,666 units at $15.00) (SEC Form 4)

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    9/16/25 6:09:13 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nussbaum Ran converted options into 411,681 shares and bought $15,000,000 worth of shares (1,000,000 units at $15.00) (SEC Form 4)

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    9/16/25 4:15:05 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Pontifax Management 4 G.P. (2015) Ltd. bought $15,000,000 worth of shares (1,000,000 units at $15.00) and converted options into 411,681 shares (SEC Form 4)

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    9/16/25 4:15:07 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on LB Pharmaceuticals

    Roth Capital initiated coverage of LB Pharmaceuticals with a rating of Buy

    1/9/26 9:05:22 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on LB Pharmaceuticals with a new price target

    Stifel initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $27.00

    10/6/25 8:30:35 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on LB Pharmaceuticals with a new price target

    Piper Sandler initiated coverage of LB Pharmaceuticals with a rating of Overweight and set a new price target of $78.00

    10/6/25 8:30:14 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    SEC Filings

    View All

    SEC Form S-1 filed by LB Pharmaceuticals Inc

    S-1 - LB PHARMACEUTICALS INC (0001691082) (Filer)

    4/6/26 4:05:42 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by LB Pharmaceuticals Inc

    S-8 - LB PHARMACEUTICALS INC (0001691082) (Filer)

    3/26/26 5:01:36 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by LB Pharmaceuticals Inc

    10-K - LB PHARMACEUTICALS INC (0001691082) (Filer)

    3/26/26 4:32:17 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Lenz Robert A.

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    3/10/26 4:19:34 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Lenz Robert A.

    3 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    3/10/26 4:16:37 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Large owner Deep Track Biotechnology Master Fund, Ltd.

    4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)

    2/10/26 4:30:04 PM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LBRX
    Leadership Updates

    Live Leadership Updates

    View All

    LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

    NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced the appointment of Robert Lenz, M.D., Ph.D. to its Board of Directors. "We are delighted to welcome Rob to our Board as his depth of expertise in neuroscience R&D brings significant value to LB Pharma at a time when we are advancing LB-102 into late-stage clinical development across multiple indications," said Heather Turner, Chief Executive Officer of LB Pharmaceuticals

    3/9/26 8:00:00 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

    NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance. "We are delighted to welcome Minako to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Dr. Pazdera has broad expertise encompassing both financial and strateg

    1/21/26 8:00:00 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture

    NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture. "We are pleased to welcome Ellen and Lindsay to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Ms. Rose has extensive experience in corporate communications, investor relations, and patient advocacy within the biopharma industry. Ms. Beaupre is a sea

    1/6/26 7:00:00 AM ET
    $LBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care